Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
Related Posts
Sakowitz S, Bakhtiyar SS, Mallick S, Pereira S, Nelson JS, Parikh R, Higgins RSD, Shemin RJ, Benharash P. Insurance-Based Disparities in Cardiac Allograft Vasculopathy After[...]
Fu R, Meng D, Han X, Liu L, Chen C, Zheng R, Zhao Y, Zhang X, Lin X, Hasani M, Song Y, Liang T, Wen[...]
Waggoner T, Garcia S, Chakravarty T, Makar M, Latib A, Kipperman RM, Zahr F, Hanson I, Sinha AK, Sharma RP, Depta JP, Castellanos JA, Kodali[...]